Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27860277 | 0.88 | ALDH1A1 (0.44) | PDPK1ALDH1A1MEN1KMT2ADGAT1 | |
| SCHEMBL12069956 | 0.87 | MEN1 (0.46) | PDPK1MTNR1BALDH1A1MEN1KMT2A | |
| SCHEMBL28679792 | 0.84 | DGAT1 (0.47) | PDPK1MTNR1BMEN1KMT2ABMP1 | |
| SCHEMBL25840109 | 0.84 | MAOB (0.52) | ALDH1A1MAOB | |
| SCHEMBL13034145 | 0.84 | MEN1 (0.53) | PDPK1MTNR1BALDH1A1MEN1KMT2A | |
| SCHEMBL27615919 | 0.80 | MTNR1B (0.46) | PDPK1MTNR1BALDH1A1BMP1DGAT1 | |
| SCHEMBL14720326 | 0.79 | RAD52 (0.43) | ALDH1A1DGAT1 | |
| SCHEMBL3883372 | 0.79 | PDPK1 (0.56) | PDPK1MTNR1BBMP1DGAT1PYCR1 | |
| SCHEMBL1241995 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL25840107 | 0.77 | MAOB (0.50) | ALDH1A1MEN1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2744333-B1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-10-05 | — | — | EP | disclosed |
| US-9084794-B2 | Fatty acid synthase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property (No2) Limite (GB) | 2014-07-10 | — | — | US | disclosed |
| EP-2744333-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013028447-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194415-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS2, FADS1 | PDPK1 435/4885MTNR1B 3877/4885ALDH1A1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.